Richard Burr: “Are those in the fiscal year 2011-12 advance funding requests anticipated or required changes in the law to release…”

Ms. Kotagal's refusal to continue these common-sense measures speaks volumes of her lack of commitment to due process and transparency.

The faster, more predictable, and more accountable the programs are, the more patients stand to benefit from lifesaving, innovative drugs and devices.

I went through a litany in my opening statements of the deficiencies in what FDA committed to and what they missed.

I was surprised and frustrated to hear that these funds were overwhelmingly repurposed from within ASPR, including the stockpile.